ATTO
Attovia Therapeutics, Inc.
Attovia Therapeutics (ATTO) Q2 2026 earnings
Published Sep 2, 2026
AI summary
- GAAP EPS −$4.88 missed the −$4.62 consensus by $0.26, down from −$3.71 a year ago.
- Attovia reported second quarter 2026 collaboration revenue of $450,000.
- The net loss for the quarter was $20.7 million, compared to $14.4 million in the prior year period.
- Research and development expenses rose to $18.9 million as the company advanced its clinical pipeline.
- The company completed an upsized IPO with gross proceeds of $332.4 million, extending its cash runway into 2030.
Results vs analyst consensus
Revenue
Reported
$450K
Consensus not captured before release
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$4.88
Consensus −$4.62
Missed by $0.26GAAP EPS: −$4.88
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is in a net loss position and relies on financing to fund operations.
- Operating expenses increased significantly due to ongoing clinical and preclinical development costs.
Read original report
Source: Attovia Therapeutics, Inc. press release · SEC Form 8-K exhibit 99.1